Immunohistochemistry plays a key role in the diagnosis of soft tissue tumors. Until recently, however, the primary purpose of immunohistochemistry in this context was simply to attempt to demonstrate a line of differentiation. Unfortunately, most traditional markers (predominantly directed against cytoplasmic determinants) show relatively limited specificity. Over the last decade or so, much more specific immunohistochemical markers for soft tissue tumors have been developed. This review will provide an update of some of the most useful new diagnostic markers, which are significantly changing clinical practice for surgical pathologists, separated into three general categories: (1) lineage-restricted transcription factors, (2) protein correlates of molecular alterations, and (3) diagnostic markers identified by gene expression profiling.
Immunohistochemistry plays a key role in the diagnosis of soft tissue tumors. Until recently, however, the primary purpose of immunohistochemistry in this context was simply to attempt to demonstrate a line of differentiation. Unfortunately, most traditional markers (predominantly directed against cytoplasmic determinants) show relatively limited specificity. For example, smooth muscle (a) actin (SMA) is not only a marker of smooth muscle neoplasms but is also typically expressed by myofibroblastic lesions; SMA may sometimes also be detected in essentially any neoplasm showing spindle cell morphology (eg, sarcomatoid carcinoma). S100 protein (S100B), the most widely used Schwann cell marker, is consistently expressed in benign nerve sheath tumors and more variably in a subset of malignant peripheral nerve sheath tumors, but is also positive in melanocytic, cartilaginous, and myoepithelial tumors, as well as chordoma, interdigitating dendritic cell sarcoma, Langerhans cell histiocytosis, and occasional carcinomas (most notably, breast carcinoma). Over the last decade or so, much more specific immunohistochemical markers for soft tissue tumors have been developed. This review will provide an update of some of the most useful new diagnostic markers, which are significantly changing clinical practice for surgical pathologists, separated into three general categories: (1) lineage-restricted transcription factors, (2) protein correlates of molecular alterations, and (3) diagnostic markers identified by gene expression profiling (Table 1) .
Lineage-restricted transcription factors
Antibodies that recognize nuclear transcription factors are increasingly finding applications in surgical pathology, such as the determination of possible anatomic sites for a carcinoma of unknown primary. Some of these markers (eg, TTF1 and CDX2) have been available in most clinical immunohistochemistry laboratories for over a decade. Other markers (eg, PAX8) have more recently been introduced into clinical practice. Until recently, few antibodies directed against transcription factors have been used for the diagnosis of soft tissue tumors.
The most widely used lineage-specific transcription factor for soft tissue tumors is myogenin (MYF4), whose expression is limited to skeletal muscle cells. 1 Myogenin is indispensable in the diagnosis of rhabdomyosarcoma, and can also be applied to confirm the presence of heterologous rhabdomyoblastic differentiation in other tumor types (eg, dedifferentiated liposarcoma and malignant peripheral nerve sheath tumor). 2 The extent of staining correlates with histologic type: whereas diffuse nuclear reactivity for myogenin is typical of alveolar rhabdomyosarcoma, embryonal rhabdomyosarcoma usually shows more heterogeneous staining (in 30-70% of tumor cells; Figure 1 ). 3 Pleomorphic rhabdomyosarcoma and spindle cell/sclerosing rhabdomyosarcoma may show only limited myogenin expression in a small subset of cells. 4, 5 MYOD1 (MYF3) is another skeletal muscle-specific transcription factor. Available antibodies may be more difficult to optimize than those directed against myogenin and sometimes show cytoplasmic background staining. 1 The expression of two related ETS family transcription factors is relatively restricted to endothelial cells and derived neoplasms. Although FLI1 (most famous for its role in the Ewing sarcoma translocation; see below) is expressed in nearly all endothelial lesions, 6 FLI1 is also positive in some normal lymphocytes, lymphoblastic lymphomas, and a subset of a wide range of mesenchymal neoplasms. 7, 8 Consequently, FLI1 has limited utility pseudomyogenic hemangioendotheliomas, and even poorly differentiated (epithelioid and spindle cell) angiosarcomas, which are particularly challenging to diagnose (Figure 2 ), but in almost no other mesenchymal neoplasms. 9, 10 Of note, some anti-ERG antibodies show cross-reactivity with FLI1, reducing the specificity of such reagents. Immunoreactivity for ERG may also be observed in epithelioid sarcomas, particularly using antibodies that recognize the N-terminus of ERG; 11, 12 an antibody directed against the C-terminus of ERG is rarely positive in epithelioid sarcoma. 12 ERG is also positive in a selected group of tumors that harbor translocations involving ERG: B50% of prostatic adenocarcinomas, 5-10% of Ewing sarcomas, and a small subset of acute myeloid leukemias. 13 Brachyury (T) is a transcriptional activator involved in the development of the notochord. 14 Nuclear expression of brachyury is a consistent feature of chordoma ( Figure 3 ), which is a helpful diagnostic immunohistochemical finding to distinguish this tumor type from potential histologic mimics, including chondrosarcoma, metastatic carcinoma, and myoepithelial tumors. [14] [15] [16] [17] No other consistently brachyury-positive tumor types have been identified. Of note, a subset of chordomas show copy number gains at the T locus. 18 T gene duplications have been identified as a susceptibility factor for familial chordoma, 19 and single-nucleotide variants in T are also associated with a risk of developing chordoma. 20 SOX10 is a member of the SOX (SRY-related HMG-box) family of transcription factors that is important for embryonic development and cell fate determination of the neural crest and peripheral nervous system. 21 As such, SOX10 is a relatively specific marker for neuroectodermal neoplasms, consistently expressed in benign nerve sheath tumors, clear cell sarcoma, and melanoma (including desmoplastic and spindle cell variants; Figure 4 ). [21] [22] [23] Unfortunately, SOX10 shows lower sensitivity for malignant peripheral nerve sheath tumors (30-50%) and, when positive, is usually detected in only a small subset of tumor cells ( Figure 4 ). 22, 24 Reactivity for SOX10 is also observed in astrocytomas, myoepithelial tumors, selected other types of salivary gland neoplasms, and a subset of breast carcinomas, particularly basal-like, 'triple-negative, ' and metaplastic carcinomas. 21, 25, 26 The most recent addition to this group of markers is SATB2 (special AT-rich sequence-binding protein 2).
SATB2 is a nuclear matrix protein that plays a critical role in osteoblast lineage commitment. 27 SatB2 knockout mice show impaired osteoblast differentiation and craniofacial defects. 27 Deletion of SATB2 also partially underlies the craniofacial malformations observed in the rare human chromosome 2q32-q33 deletion syndrome. 28 SATB2 is a sensitive and specific immunohistochemical marker of osteoblastic differentiation in bone and soft tissue tumors. 29 Although nuclear staining for SATB2 is seen in nearly all cases of osteosarcoma ( Figure 5 ), SATB2 expression is also a feature of benign osteoblastic neoplasms, as well as other sarcoma types with heterologous osteosarcomatous differentiation (eg, dedifferentiated chondrosarcoma and dedifferentiated liposarcoma). 29 As such, SATB2 expression must be interpreted carefully in the context of histologic features and radiologic findings. SATB2 may be a particularly helpful diagnostic adjunct for osteosarcoma in two specific settings: (1) when the histologic features of the matrix are equivocal (ie, osteoid vs hyalinized collagen) and (2) when the biopsy only samples tumor with an undifferentiated appearance. Of note, soft tissue tumors with abundant hyalinized collagen (eg, sclerosing epithelioid fibrosarcoma (SEF) and sclerosing rhabdomyosarcoma) are consistently negative for SATB2. 29 SATB2 has previously also been shown to be a sensitive and specific marker for colorectal origin among carcinoma. 30 Protein correlates of molecular alterations in soft tissue tumors b-Catenin is the product of the CTNNB1 gene involved in the Wnt signaling pathway (along with APC). Mutations in CTNNB1 are found in 85-90% of sporadic desmoid tumors; 31 patients with familial adenomatous polyposis and a germline mutation in APC also develop desmoid fibromatosis (Gardner syndrome), especially in the mesentery of the small intestine. Immunohistochemistry for b-catenin shows aberrant nuclear staining (as opposed to the normal cell membranous pattern of staining) in the majority of cases of desmoid fibromatosis ( Figure 6 ) and is therefore useful to confirm the diagnosis, particularly in core needle biopsies or other limited samples in which the distinction between scar tissue and desmoid tumor (or other bland spindle cell neoplasms) may be challenging. [32] [33] [34] Of note, nuclear immunoreactivity may sometimes be limited in extent; examination under high magnification is often required to identify nuclear staining.
Although b-catenin immunohistochemistry has a reasonable sensitivity for desmoid fibromatosis (70-90%) and is consistently negative in other intra-abdominal mesenchymal neoplasms (including gastrointestinal stromal tumors (GISTs) and smooth muscle tumors), 32, 34 it is not entirely specific; a subset of solitary fibrous tumors (20-40%) and low-grade myofibroblastic sarcomas (30%) also show nuclear staining. 35 b-Catenin must therefore be interpreted carefully in the context of clinical findings and morphology.
Atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma are characterized by supernumerary ring and giant marker chromosomes, composed of amplified material from the long arm of chromosome 12 (q13B15), within which several oncogenes are located, leading to overexpression of MDM2 and CDK4. 36 Nuclear reactivity for MDM2 and CDK4 is therefore highly sensitive for well-differentiated and dedifferentiated liposarcomas, but is not entirely specific, as some other spindle cell and pleomorphic sarcomas (such as malignant peripheral nerve sheath tumor, myxofibrosarcoma, and rhabdomyosarcoma) show nuclear staining in a subset of cases. [37] [38] [39] [40] Combined positive staining for both MDM2 and CDK4 is much more specific. 37 Identification of MDM2 gene amplification by fluorescence in situ hybridization (FISH) is highly specific for well-differentiated and dedifferentiated liposarcoma (more specific than immunohistochemistry). 41 Nonetheless, in the proper context, immunohistochemistry for MDM2 and CDK4 can be very helpful in differential diagnosis, particularly in the distinction between well-differentiated liposarcoma and spindle cell/ pleomorphic lipoma or conventional lipoma, and between dedifferentiated liposarcoma and other high-grade sarcomas in a core needle biopsy of a large retroperitoneal or intra-abdominal mass ( Figure 7 ). Our understanding of the molecular genetics of these tumor types has also helped clarify the nosology of so-called 'inflammatory malignant fibrous histiocytoma,' nearly all cases of which in fact represent not a distinct tumor type but a morphologic pattern in dedifferentiated liposarcoma ( Figure 7 ). 42 SMARCB1 (also known as INI1 and SNF5) is a member of the SWI/SNF multisubunit chromatin remodeling complex that plays a fundamental role in regulating transcription. 43 SMARCB1 is ubiquitously expressed in normal cells. Biallelic inactivation of SMARCB1 is essentially a defining feature of malignant rhabdoid tumors of infancy. 44 Loss of normal nuclear expression of SMARCB1 is useful to confirm the diagnosis of this rare, aggressive tumor type (Figure 8) . 45, 46 More recent studies have also demonstrated a tumor suppressor role of SMARCB1 in epithelioid sarcoma (both conventional and proximal type). [47] [48] [49] Homozygous deletion of the SMARCB1 locus is also common in epithelioid sarcoma, 50 and B95% of epithelioid sarcomas show loss of SMARCB1 protein expression by immunohistochemistry (Figure 8) . 48 Immunohistochemistry is therefore helpful in differential diagnosis, as metastatic carcinomas and epithelioid vascular neoplasms (angiosarcoma and epithelioid hemangioendothelioma) consistently retain SMARCB1 protein expression (Figure 8 ). 48 Several other tumor types also show loss of SMARCB1 expression, including renal medullary carcinomas, B50% of epithelioid malignant peripheral nerve sheath tumors, and a subset of myoepithelial carcinomas of soft tissue, extraskeletal myxoid chondrosarcomas, and poorly differentiated chordomas. 43, 48, 51, 52 Familial paraganglioma syndrome, the most common inherited paraganglioma predisposition syndrome, is caused by germline mutations in the succinate dehydrogenase (SDH) subunit genes. 53, 54 The SDH complex resides in the inner mitochondrial membrane, where it participates in both the citric acid cycle (catalyzing the oxidation of succinate to fumarate) and the electron transport chain (complex II). Mutations in SDH subunit genes lead to loss of protein expression and enzyme function. Immunohistochemistry for SDHB shows loss of the normal granular cytoplasmic (mitochondrial) staining pattern in such tumors, irrespective of which gene is mutated. 54 Similarly, immunohistochemistry for SDHB can help identify a clinically and histologically distinctive class of GISTs of the stomach, referred to as SDH-deficient GISTs (Figure 9 ). [55] [56] [57] [58] [59] GISTs with loss of SDH expression are a feature of Carney-Stratakis syndrome, a variant of familial paraganglioma syndrome in which patients also develop such GISTs, as well as Carney triad (paraganglioma, gastric GIST, and pulmonary chondroma), although the genetic basis of the latter non-familial syndrome has not been determined. 58 The rare GISTs that present in childhood are nearly all SDH-deficient, and recent studies have shown that 8-10% of gastric GISTs overall are also SDH-deficient. 56, 57 The molecular mechanisms underlying SDH dysfunction in the majority of SDH-deficient GISTs (outside of the Carney-Stratakis syndrome) are unknown; SDH subunit mutations are found in only a subset of patients. 53, 56 SDH-deficient GISTs (previously briefly referred to as 'pediatric-type' or 'type 2' GISTs) show a distinctive multinodular or plexiform growth pattern and epithelioid or mixed morphology, and can therefore be recognized histologically ( Figure 9) . 55, 59, 60 Similar to conventional KITmutant GISTs, SDH-deficient GISTs are usually positive for KIT, DOG1 (discovered on GIST1), and CD34 by immunohistochemistry. Risk assessment criteria currently widely used for GIST do not reliably predict behavior for this class of tumors, although they have a significant potential for metastasis to lymph nodes (unlike conventional GIST), peritoneum, and liver. 53, 60 Metastases are clinically indolent (some patients with metastatic disease survive without therapy for decades) and show limited (if any) response to imatinib. Most recently, SDHA mutations have been identified as a common cause of SDH-deficient GIST (around one-third of all such tumors); of note, loss of SDHA protein expression reliably predicts the presence of SDHA mutations (unlike loss of SDHB, which does not indicate the gene involved, if any). [61] [62] [63] [64] SDH-deficient GISTs with mutations in other SDH subunit genes (and those without identifiable SDH mutations) retain normal cytoplasmic staining for SDHA. 62, 64 A small subset of renal cell carcinomas also shows loss of SDHB protein expression; some (but not all) such tumors are characterized by a distinctive oncocytoid cytomorphology. 65, 66 Several antibodies that recognize protein products of gene rearrangements in sarcomas can be applied clinically for diagnostic surgical pathology. Alveolar soft part sarcoma harbors the translocation t(X;17), which leads to the ASPSCR1-TFE3 fusion and overexpression of the TFE3 protein. 67 A similar translocation is found in Xp11 translocation renal cell carcinomas, 68 and TFE3 rearrangements have recently been identified in a small subset of PEComas 69 and a distinctive subset of epithelioid hemangioendotheliomas. 70 By immunohistochemistry, these tumors show nuclear staining for TFE3, which can be used to confirm the diagnosis (Figure 10) . [69] [70] [71] The most common translocation in Ewing sarcoma is t (11;22) , found in B90% of cases. This translocation leads to EWSR1-FLI1 fusion and overexpression of the FLI1 protein. By immunohistochemistry, Ewing sarcomas usually show strong nuclear staining for FLI1. 8, 72 However, as mentioned previously, FLI1 is also expressed in endothelial cells and derived neoplasms, some non-neoplastic lymphocytes, lymphoblastic lymphomas, and occasionally in a variety of other tumor types. [6] [7] [8] [9] Given its lack of specificity, FLI1 immunohistochemistry is not particularly helpful in differential diagnosis. As mentioned above, ERG is an excellent marker for endothelial neoplasms. 9 In addition, a small subset of Ewing sarcomas (ie, those with EWSR1-ERG rearrangement) is strongly positive for ERG as well. 73 Approximately 50% of inflammatory myofibroblastic tumors (IMTs) harbor rearrangements of the ALK locus, which usually results in ALK protein expression detectable by immunohistochemistry. [74] [75] [76] [77] [78] Interestingly, the pattern of ALK staining appears to correlate with the fusion partner. Most translocations (involving the fusion partners TPM3, TPM4, CARS, ATIC, SEC31A, and CLTC) result in cytoplasmic staining, whereas a nuclear membrane pattern of staining is seen with the RANBP2 fusion partner (a nuclear pore protein; Figure 11 ). 79 IMTs with RANBP2-ALK fusion have a predilection for the omentum and mesentery; show distinctive (epithelioid) morphology, myxoid stroma, and often a neutrophilic inflammatory infiltrate; and pursue an aggressive clinical course (leading to the designation 'epithelioid inflammatory myofibroblastic sarcoma'). 79 As this distinctive IMT variant can be positive for CD30, it may be confused with anaplastic large-cell lymphoma; desmin expression is helpful to distinguish among these possibilities, as desmin is consistently negative in this lymphoma type. Among mesenchymal neoplasms, ALK expression is not entirely specific for IMT; eg, it is also positive in some rhabdomyosarcomas and malignant peripheral nerve sheath tumors. 74, 80 A subset of neuroblastomas and pulmonary adenocarcinomas also overexpress ALK (the latter usually secondary to EML4-ALK fusion). 81, 82 Most other fibroblastic/myofibroblastic tumors (including desmoid fibromatosis, nodular fasciitis, myofibroma, and infantile fibrosarcoma) are negative for ALK. 74 Recently, a NAB2-STAT6 fusion has been identified by several independent groups as a consistent feature of solitary fibrous tumors (including cellular examples formerly known as 'hemangiopericytoma,' as well as histologically atypical and malignant variants). [83] [84] [85] The so-called 'meningeal hemangiopericytoma' also harbors this fusion gene, supporting the classification of this tumor type with solitary fibrous tumor (similar to examples arising in soft tissue and at visceral sites). 86 As these two fusion partners reside in close proximity on chromosome 12q13, this gene fusion cannot be identified by conventional FISH analysis. 84 NAB2-STAT6 fusion leads to high-level nuclear expression of the STAT6 protein. 86 By immunohistochemistry, nearly all cases of solitary fibrous tumor (including cellular and malignant variants) show strong nuclear staining for STAT6 (Figure 12) , whereas other spindle cell neoplasms that might be considered in the differential diagnosis are consistently negative. 86, 87 Diagnostic markers identified by gene expression profiling DOG1 was shown to be highly expressed in GIST by gene expression profiling. 88 Also known as ANO1 (anoctamin 1) and TMEM16A, this protein is a calcium-activated chloride channel expressed in normal interstitial cells of Cajal that plays a fundamental role in generation of slow waves during peristalsis. 89 DOG1 is a highly sensitive and specific marker for GIST, and it is also positive in a subset of KIT-negative tumors ( Figure 13 ). [90] [91] [92] [93] DOG1 is most helpful as a diagnostic adjunct for epithelioid gastric and omental GISTs with PDGFRA mutations (which are often KIT negative or show limited KIT immunoreactivity). Notable other tumor types that sometimes express DOG1 include a small subset of uterine-type retroperitoneal leiomyomas and synovial sarcomas. 93 TLE1 (transducin-like enhancer of split 1) is a transcriptional corepressor that inhibits Wnt signaling. Using gene expression profiling, TLE1 was found to be an excellent discriminator of synovial sarcoma from other sarcoma types. 94 By immunohistochemistry, TLE1 shows moderate-tostrong, diffuse nuclear staining in the majority of synovial sarcomas (80-90%) (Figure 14) . [95] [96] [97] [98] TLE1 is a relatively specific marker for synovial sarcoma that can be helpful in differential diagnosis, as it is only positive in a small subset of malignant peripheral nerve sheath tumors and solitary fibrous tumors (usually with only weak staining), and it is consistently negative in Ewing sarcomas (which can be mistaken for poorly differentiated synovial sarcomas). 95, 97 MUC4 is a high-molecular-weight transmembrane glycoprotein expressed on the surface of some glandular epithelial cell types. Gene expression profiling has recently indicated that this epithelial mucin is highly expressed by low-grade fibromyxoid sarcoma (LGFMS), 99 which is typically characterized by the t(7;16) translocation, resulting in FUS-CREB3L2 rearrangement, or more rarely t(11;16), resulting in FUS-CREB3L1 fusion. 100, 101 MUC4 is a highly sensitive and specific immunohistochemical marker for LGFMS among spindle cell neoplasms (MUC4 is negative in soft tissue perineurioma, malignant peripheral nerve sheath tumor, solitary fibrous tumor, desmoid fibromatosis, and intramuscular/cellular myxoma) and can therefore be helpful in confirming the diagnosis (Figure 15 ). 102 SEF is a rare aggressive sarcoma type composed of cords of epithelioid cells in a densely hyalinized stroma. Until recently, no helpful diagnostic markers were available. Some cases of SEF harbor the same genetic alterations as, and also may show hybrid histologic features with LGFMS. 100, 103 Hybrid tumors with both LGFMS and SEF components, as well as B70% of 'pure' SEF cases, are strongly positive for MUC4 (Figure 15 ). 103 Immunohistochemistry for MUC4 can be helpful in differential diagnosis, as nearly all other epithelioid bone and soft tissue tumors are negative for this marker, with the exception of the glandular component of biphasic synovial sarcoma, although this tumor type is unlikely to pose diagnostic problems. 103, 104 GRIA2 is a subunit of a class of glutamate receptors involved in the transmission of excitatory synaptic signals in the central nervous system. In a recent study, global gene expression profiling identified GRIA2 as the top upregulated gene in solitary fibrous tumors (100-fold higher than control tissues). 84 By immunohistochemistry using a tissue microarray, GRIA2 was positive in the majority of solitary fibrous tumors and was negative in other spindle cell neoplasms. 84 These preliminary observations require confirmation in additional studies.
Summary
We have entered a new era of diagnostic immunohistochemistry for soft tissue tumor pathology. Antibodies directed against lineage-restricted transcription factors are helpful and relatively specific diagnostic markers. Molecular genetic findings can lead to new inexpensive and rapid diagnostic tests in the form of a single immunohistochemical stain. Finally, gene expression profiling can provide novel markers to discriminate among classes of histologically similar tumors, in some cases potentially obviating confirmation by molecular genetic techniques.
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